Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 314

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 314
---
     | Executive Chairperson and Director                           |
| Stephen Ma                        |     |  52 |     | Chief Financial Officer, Senior Vice President and Secretary |
| Non-employee Directors:           |     |     |     |                                                              |
| Jay Chun, M.D., Ph.D.(1)(2)(3)(4) |     |  61 |     | Director                                                     |
| Dorman Followwill(1)(2)(3)        |     |  61 |     | Director                                                     |
| Annu Navani(4)                    |     |  54 |     | Director                                                     |
| Yue Alexander Wu, Ph.D.(1)(2)(3)  |     |  61 |     | Director                                                     |

| (1) | Member of the Audit Committee. |

| (2) | Member of the Compensation Committee. |

| (3) | Member of the Nominating and Corporate Governance Committee. |

| (4) | Member of the Commercialization and Transaction Committee. |

Executive Officers Jaisim Shah .Mr. Shah has served as our Chief Executive Officer and President and a member of our Board since November 10, 2022. Prior to that, he served as Legacy Scilex’s President, Chief Executive Officer and a board member from March 2019 to November 2022. He has more than 25 years of global biopharma experience, including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as the Chief Executive Officer and a board member of Semnur from its inception in 2013 until its acquisition by Legacy Scilex in March 2019. Mr. Shah has served on the board of directors of Scilex Pharmaceuticals Inc., our wholly owned subsidiary (“Scilex Pharma”), since November 2016. Prior to his time at Semnur, Mr. Shah was a consultant to several businesses, including Sorrento, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr. Shah led a successful sale of Elevation Pharmaceuticals, Inc. to Sunovion Pharmaceuticals Inc. in September 2012. Prior to his time at Elevation Pharmaceuticals, Inc., Mr. Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to his time at Zelos Therapeutics, Inc., Mr. Shah was the Senior Vice President and Chief Business Officer at CytRx Corporation, a bi